Sterile injectable drug products based on biologic drug substances often pose storage and handling challenges. Many biologics are unstable at room temperature, and some may degrade when exposed to light, oxygen, shock, pressure changes, and other atmospheric conditions.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
Capacity for sterile injectable manufacturing was tight before the COVID-19 pandemic.[140] The increasing number of biologic drugs has created growing demand overall. Meanwhile, the growing complexity of next-generation drug substances and the increasing role that small and emerging biopharma companies are playing in this space have led to an increase in the reliance on contract manufacturing for sterile injectable drug substances and drug products (see below).
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
The speed at which COVID-19 vaccines were developed and commercial-scale processes implemented revealed the agility with which the biopharmaceutical industry can move when needed. Increased speed to market has become essential in recent years as competition in the marketplace becomes markedly greater. For potentially curative treatments, being first to market can be a requirement for success.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
Automation is not only an enabler of continuous manufacturing; for forward-looking injectables manufacturers, it is a means of managing the increasing complexity of parenteral drug production.[26] In addition to reducing the risk of contamination, automated and closed systems increase the safety for operators and the environment when processing highly potent drugs. Elimination of repetitive motions performed by operators also increases efficiency, while the ability to collect and analyze large quantities of data enables measurable process improvements.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
Drug manufacturers are expected by regulatory agencies to take a risk-based approach to ensuring quality and safety. There are strongly differing opinions, however, on what approaches to sterile injectable drug manufacturing present acceptable levels of risk.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
One of the key concerns with generic sterile injectables, is the high number of drug shortages that have occurred in the last 20 years.[126] The inability of generic drug manufacturers to charge sustainable prices is thought to be one of the key causes of these shortages.[127] Suppressed generic drug prices have resulted in a lack of investment in new generic products, a lack of resources to upgrade manufacturing facilities and thus comply with current good manufacturing practices (cGMPs) and maintain drug quality, and fewer players in the market.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
Hurricane Helene, which struck the southeastern U.S. in late September 2024, caused significant flooding at Baxter International’s North Cove facility in Marion, North Carolina. This plant is a major producer of IV fluids and peritoneal dialysis solutions, supplying approximately 60% of the U.S. market. The flooding led to a temporary shutdown of the facility, resulting in nationwide shortages of these critical medical supplies.[129]
In response to the shortages, Baxter implemented several measures:
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
Sustainability concerns are becoming increasingly common in the pharmaceutical industry, and the sterile injectables market is an active area of discussion, driven largely by the economics of waste. Any wasted final drug product is necessarily more costly than most other steps in the manufacturing value chain.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.